Jimmy Wu
Internal Medicine · Garden Grove, CANPI 1982647939
Payments from drug & device makers
Across 546 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- Boehringer Ingelheim$2K
- GSK$1K
- Novo Nordisk$1K
- Bayer$1K
- plus $7K from 22 others
What the payments were for
- Food & beverage$16,82599%
- Education$2111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $2,555 |
| AbbVie(2 entities) | 75 | $2,055 |
| Boehringer Ingelheim | 44 | $1,700 |
| GSK | 33 | $1,352 |
| Novo Nordisk | 49 | $1,337 |
| Bayer | 40 | $1,144 |
| Lilly USA, LLC | 26 | $944 |
| Abbott | 21 | $823 |
| Amarin Pharma, Inc. | 30 | $755 |
| Gilead | 11 | $631 |
| Johnson & Johnson | 12 | $600 |
| Merck | 25 | $523 |
| Teva Pharmaceuticals USA, Inc. | 11 | $424 |
| Novartis | 11 | $367 |
| Pfizer | 16 | $352 |
| Ironwood Pharmaceuticals, Inc | 5 | $223 |
| Ardelyx, Inc. | 7 | $207 |
| Amgen | 9 | $181 |
| Corcept Therapeutics | 8 | $167 |
| Kowa Pharmaceuticals America, Inc. | 12 | $162 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $143 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 5 | $95 |
| Sanofi Pasteur Inc. | 3 | $83 |
| Radius Health, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,036 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 264 | $294,734 |
| CreonLipase/Protease/Amylase | 63 | $182,302 |
| JanuviaSitagliptin Phosphate | 163 | $162,089 |
| OzempicSemaglutide | 92 | $126,081 |
| FarxigaDapagliflozin Propanediol | 123 | $98,068 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $72,873 |
| KerendiaFinerenone | 80 | $69,175 |
| RybelsusSemaglutide | 46 | $59,784 |
| LinzessLinaclotide | 62 | $57,963 |
| VascepaIcosapent Ethyl | 63 | $33,355 |
| EntrestoSacubitril/Valsartan | 30 | $30,612 |
| Icosapent Ethyl | 64 | $28,300 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $28,142 |
| XareltoRivaroxaban | 19 | $25,831 |
| ZenpepLipase/Protease/Amylase | 11 | $25,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,700 | $294,734264 claims |
| AbbVieCreon, Linzess, Restasis | $2,055 | $257,122152 claims |
| Novo NordiskOzempic, Rybelsus | $1,337 | $185,865138 claims |
| MerckJanuvia, Janumet | $523 | $175,945178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,555 | $126,210169 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta | $1,352 | $100,358223 claims |
| BayerKerendia | $1,144 | $69,17580 claims |
| PfizerEliquis, Nurtec Odt | $352 | $36,79832 claims |
| NovartisEntresto | $367 | $30,61230 claims |
| Johnson & JohnsonXarelto | $600 | $25,83119 claims |
| Aimmune Therapeutics, Inc.Zenpep | $125 | $25,57711 claims |
| Lilly USA, LLCTrulicity | $944 | $17,46816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Garden Grove
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.